|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2009-4-30
|
|
pubmed:abstractText |
S-1 is an oral anticancer agent that combines tegafur (FT) with 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate. The recommended initial dose of S-1 is 120 mg/day for patients with a body surface area (BSA) of > or =1.5 m(2) in Japan.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1569-8041
|
|
pubmed:author |
pubmed-author:AkiyamaYY,
pubmed-author:AndoYY,
pubmed-author:ArakiKK,
pubmed-author:EndoHH,
pubmed-author:FujitaKK,
pubmed-author:IchikawaWW,
pubmed-author:KawaraKK,
pubmed-author:KodamaKK,
pubmed-author:MiwaKK,
pubmed-author:MiyaTT,
pubmed-author:NagashimaFF,
pubmed-author:NarabayashiMM,
pubmed-author:SasakiYY,
pubmed-author:SunakawaYY,
pubmed-author:TanakaRR,
pubmed-author:YamamotoWW
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
946-9
|
|
pubmed:meshHeading |
pubmed-meshheading:19150953-Administration, Oral,
pubmed-meshheading:19150953-Aged,
pubmed-meshheading:19150953-Aged, 80 and over,
pubmed-meshheading:19150953-Antimetabolites, Antineoplastic,
pubmed-meshheading:19150953-Area Under Curve,
pubmed-meshheading:19150953-Body Surface Area,
pubmed-meshheading:19150953-Drug Combinations,
pubmed-meshheading:19150953-Drug Dosage Calculations,
pubmed-meshheading:19150953-Female,
pubmed-meshheading:19150953-Humans,
pubmed-meshheading:19150953-Japan,
pubmed-meshheading:19150953-Male,
pubmed-meshheading:19150953-Middle Aged,
pubmed-meshheading:19150953-Neoplasms,
pubmed-meshheading:19150953-Oxonic Acid,
pubmed-meshheading:19150953-Tegafur,
pubmed-meshheading:19150953-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Fixed dosing and pharmacokinetics of S-1 in Japanese cancer patients with large body surface areas.
|
|
pubmed:affiliation |
Department of Medical Oncology, Saitama International Medical Center-Comprehensive Cancer Center, Saitama Medical University, Hidaka, Saitama, Japan.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, Non-U.S. Gov't
|
